High Lipoprotein(a) Levels Linked to Persistent Cardiovascular Risk

A new study suggests elevated lipoprotein(a),or Lp(a),levels are linked to residual cardiovascular risk, including higher odds of stroke and cardiovascular death, even among people on standard treatments.

• High Lp(a) levels were linked to significantly increased risk of major cardiovascular events, including stroke and cardiovascular death.
• The association was strongest in those with existing cardiovascular disease, suggesting Lp(a) contributes to ongoing risk even with standard treatment.
• No clear link was found between elevated Lp(a) and heart attack risk.
• The findings support Lp(a) as an important, largely genetic risk factor that could help improve cardiovascular risk assessment.

Understanding Lipoprotein(a)

Lipoprotein(a) is a cholesterol-carrying particle similar to low-density lipoprotein (LDL), or “bad” cholesterol. Unlike LDL, Lp(a) contains proteins that promote blood clotting, potentially making it a greater cardiovascular risk factor. Source: NHLBI.

Lp(a) contributes to residual cardiovascular risk,the risk of events despite lowered LDL. Levels are largely genetic, with 70–90% determined by the LPA gene. About 1 in 5 people have elevated levels. Source: AHA.

Study Details and Key Findings

Researchers analyzed data from 20,070 adults aged 40+ (average age ~65 years, ~65% male) in three NIH trials: ACCORD, PEACE, and SPRINT. For related diabetes management insights, see Ozempic Revolutionizing Obesity Treatment?.

Participants were grouped by Lp(a) levels: low (<75 nmol/L) to very high (≥175 nmol/L), and prior cardiovascular disease status. Over ~4 years median follow-up, 7.3% experienced major adverse cardiovascular events (MACE: heart attack, stroke, CV death). Learn more about obesity-related risks in GLP-1s Cut Asthma Attacks 14% in Overweight Patients.

Individuals with Lp(a) ≥175 nmol/L had significantly higher risk of stroke and CV death, especially with existing CVD. No association with heart attack risk. CDC Heart Risk Factors.

“We would generally consider a Lp(a) level of over 125 nmol/L to be high. The threshold of ≥175 nmol/L identified in the study would be considered extremely high and should drive aggressive management of other cardiovascular risk factors.”

, Cheng-Han Chen, MD, interventional cardiologist, MemorialCare Saddleback Medical Center. Source.

Findings were presented at the SCAI 2026 Scientific Sessions and CAIC-ACCI Summit in Montreal. Abstract. FDA Cardiovascular Devices.

Implications for Screening and Management

Lp(a) testing is simple and inexpensive. Experts recommend testing at least once in adulthood to assess risk, particularly for those with family history or prior events. Mayo Clinic Cholesterol Testing.

For elevated levels, strategies include aggressive LDL lowering, blood pressure and diabetes control, lifestyle changes (exercise, heart-healthy diet low in sodium/saturated fat, no tobacco/alcohol), and closer monitoring.

Emerging therapies targeting Lp(a) are in development. Further research is needed for subgroups like those with kidney or peripheral artery disease. National Kidney Foundation Heart Disease.

Lp(a) measurement could enhance routine risk assessment, especially for residual risk despite LDL control. Source: AHA Journals; Source: Nature.